Clinical trial
Fibromyalgia Study In Adults
NCT00256893 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00256893 |
|---|---|
| Title | Fibromyalgia Study In Adults |
| Official title | A Randomised, Double Blind, Placebo-controlled, Parallel Group Study to Investigate the Safety and Efficacy of Controlled-release Ropinirole (CR) (1-24 mg) Administered Once Daily for 12 Weeks in Subjects With Fibromyalgia |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Fibromyalgia Syndrome, Primary |
| Intervention type | Drug |
| Interventions | ropinirole |
| Enrollment | 164 |
| Start date | Nov 1, 2004 |
| Completion | Jul 1, 2005 |
| First posted | Nov 22, 2005 |
| Last update posted | Sep 15, 2016 |
| Countries | Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Sweden, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: